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Article Information  ABSTRACT 
Received: 13th February 2020  A simple and selective LC technique is chosen for the determination of Aceclofenac and Tizanidine in 
pill indefinite quantity forms. Chromatographic process separation was achieved on a c18 column 
victimization mobile part consisting of a combination of fifty volumes of Triethylamine buffer, fifty 
volumes of acetonitrile with detection of 230nm. Dimensionality was discovered within the vary 5-15 
µg/ml for aceclofenac (r2 =0.999) and 1-3 µg /ml for tizanidine (r2 =0.998) for the number of medicine 
calculable by the planned strategies was in smart agreement with the label claim. The planned strategies 
have a sound procedure. At three completely different levels the accuracy of the strategies was assessed 
by recovery studies. The recovery experiments indicated the absence of interference from unremarkably 
encountered pharmaceutical additives showing %RSD below a pair of this technique was found to be 
precise as indicated by the repeatability analysis. All applied mathematics information proves all ways 
have valid procedure and might be used for routine analysis of pharmaceutical dose kind 
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INTRODUCTION 
Pharmaceutical analysis just means examination of 
pharmaceuticals. Webster' word reference portrays a 
pharmaceutical is a medication. An additionally fitting term for 
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a pharmaceutical is dynamic pharmaceutical fixing to remember 
it from a planned thing or prescription thing is set up by figuring 
a solution substance with idle concentration (excipients) to set 
up a drug thing that is sensible for association to patients [1]. 
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Reverse Phase High Performance Liquid Chromatography 
(RP-HPLC) 
Reverse phase chromatography uses hydrophobic bonded 
packing, usually with an octadecyl or octyl functional group and 
a polar aqueous mobile phase. Polar substances prefer the 
mobile phase and eluted first. Because the hydrophobic 
character of the solutes will increase, and followed retention will 
also increase. Generally, the lower the polarity of the 
mobile section, the upper is its eluent strength. The elution order 
of the classes of compounds in table is reversed (thus the name 
reverse-phase chromatography) [2]. 
 
Drug Profile 
Aceclofenac is a non-steroidal calming drug (NSAID) with 
stamped mitigating and pain relieving properties. It is accounted 
for to have a higher mitigating activity or if nothing else 
tantamount impacts than ordinary NSAIDs in twofold visually 
impaired investigations. Aceclofenac intensely hinders the 
cyclo-oxygenase protein (COX) that is engaged with the 
combination of prostaglandins, which are fiery middle people 
that reason torment, swelling, irritation, and fever [3]. It is orally 
regulated for the alleviation of agony and aggravation in 
osteoarthritis, rheumatoid joint pain and ankylosing spondylitis. 
Aceclofenac has a place with BCS Class II as it has poor watery 
dissolvability. It shows high porousness to infiltrate into 
synovial joints where in patients with osteoarthritis and related 
conditions, the loss of articular ligament in the territory causes 
joint torment, delicacy, solidness, crepitus, and nearby 
aggravation [4]. Aceclofenac is likewise answered to be 
compelling in other excruciating conditions, for example, dental 
and gynecological conditions. In 1991, aceclofenac was 
produced as a simple of a usually recommended NSAID, 
Diclofenac, by means of substance adjustment in push to 
enhance the gastrointestinal mediocrity of the medication. It is 
an all the more generally recommended medicate in Europe [5]. 
Through COX-2 hindrance, aceclofenac downregulates the 
generation of different provocative go betweens including 
prostaglandin E2 (PGE2), IL-1β, and TNF from the arachidonic 
corrosive (AA) pathway. Restraint of IL-6 is believed to be 
interceded by diclofenac changed over from aceclofenac [6]. 
Stifled activity of incendiary cytokines diminishes the creation 
of receptive oxygen species. Aceclofenac is appeared to 
diminished generation of N₂O in person articular chondrocytes. 
Also, aceclofenac meddles with neutrophil bond to endothelium 
by diminishing the statement of L-selectin (CD62L), which is a 
cell grip atom communicated on lymphocytes. Aceclofenac is 
proposed to fortify the amalgamation of glycosaminoglycan in 
human osteoarthritic ligament which might be interceded 
through its inhibitory activity on IL-1 creation and movement. 
The chrondroprotective impacts are created by 4'- 
hydroxyaceclofenac which stifles IL-1 interceded generation of 
promatrix metalloproteinase-1 and metalloproteinase-3 and 
meddles with the arrival of proteoglycan from chrondrocytes [7]. 
Tizanidine is a short-acting medication for the administration of 
spasticity. Tizanidine is an agonist at a2-adrenergic receptor, and 
it is very close to clonidine and apparently lessens spasticity by 
expanding presynaptic hindrance of engine neurons. In creature 
models, tizanidine has no immediate impact on skeletal muscle 
filaments or the neuromuscular intersection, and no significant 
impact on monosynaptic spinal reflexes. The impacts of 
tizanidine are most prominent on polysynaptic pathways. The 
general impact of these activities is thought to decrease 
assistance of spinal engine neurons [8]. Tizanidine reduces 
spasticity by causing presynaptic inhibition of motor neurons via 
agonist acts at Alpha-2 adrenergic receptor sites. This drug is 
centrally acting and leads to a reduction in the release of 
excitatory amino acids like glutamate and aspartate, which cause 
neuronal firing that leads to muscle spasm. The above reduction 
and excitatory neurotransmitter release results in presynaptic 
inhibition of motor neurons. The strongest effect of tizanidine 
has been shown to occur on spinal polysynaptic pathways. The 
anti-nociceptive and anticonvulsant activities of tizanidine may 
also be attributed to agonist action on Alpha-2 receptors. 
Tizanidine also binds with weaker affinity to the Alpha-1 
receptors, explaining its slight and temporary effect on the 
cardiovascular system [9, 10]. In young nursing rats, abnormal 
results were obtained in tests indicative of central nervous 
system function. Various developmental changes that may have 
been attributable to the drug were observed. It is unknown 
whether tizanidine is excreted in human milk. It is a lipid-soluble 
drug, however, and likely to be excreted into breast milk [11]. 
  
Quality investigation plays a very important role in quality 
specification establishment of chemical drugs. The numbers of 
drugs launch into the retail every year .very often there's a time 
lag from the time of launch of a drug into the market to the date 
of its insertion in pharmacopoeias. Hence, standards and 
analytical procedures for these drugs may not be available in the 
pharmacopoeias. It becomes necessary, so to develop newer 
analytical strategies for such medication [12]. 
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To develop new RP HPLC method, of pharmaceutical dosage 
form. The plan of work includes solubility determination of 
aceclofenac and tizanidine various solvents and buffers. 
Establish the maximum absorbance of each of the medication in 
UV-Visible region in numerous solvents/buffers and choosing 
the dissolving agents for HPLC methodology development. 
Optimize the mobile phase and flow rates for proper resolution 
and retention times. Validate the developed method as per ICH 
guidelines. 
 
MATERIAL AND METHOD 
Instruments Used 
The instruments which were used for this work were, UV Visible 
apparatus which was manufactured by Nicolet evolution 100, 
UV-Visible Software that was developed by Vision Pro, HPLC 
software that was developed by Spin chrome (LC solutions), 
HPLC and Electronic balance manufactured by Shimadzu(LC 
20 AT VP), Ultra sonicator which was manufactured Citizen, 
Digital Ultrasonic Cleaner, pH meter manufactured by Global 
digital, Syringe was used for injection which was manufactured 
by Hamilton, HPLC Column was obtained from Inertsil ODS 
3V(250x4.6mm) 5μm 
Reagents Used 
Water, Methanol, was used according to HPLC Grade; 
Ammonium acetate was used as per AR Grade. 
Drugs Used 
Aceclofenac and Tizanidine drugs are obtained as gift Samples 
obtained from Chandra labs; Hyd. ACENT (100/2mg) was 
obtained from local pharmacy 
 
Preparation of Mobile Phase 
A concoction of fifty volumes of triethylamine buffer 
maintaining a pH of 3.0 and same volume of acetonitrile were 
created. The mobile section was sonicated for 10min to get rid 
of gases and filtered through 0.45µ membrane for degassing 
from the mobile section 
 
Determination of Wavelength using UV Visible 
Spectroscopy [13] 
Preparation of stock solution of aceclofenac 
Accurately weighed 10 mg of aceclofenac was pass on in to a 
100 ml flask and aceclofenac was dissolved in methanol, make 
up to the 100ml with same solvent to prepare 100 µg /ml. From 
this solution pipette out 1ml and prepare up to 10ml with 
methanol to preprare 10 µg /ml of drug solution. 
Preparation of stock solution of tizanidine 
Weighed 10 mg of drug was shifted in to a 100ml volumetric 
flask and tizanidine was dissolved in methanol, make up to the 
100ml with same solvent to prepare 100µg /ml. From this 
suspension pipette out 1ml and prepare up to 10ml with 
methanol to preprare 10 µg /ml of drug solution. 
Method Development 
Trial – 1 
The Mobile phase that is used are Phosphate buffer: Acetonitrile: 
Methanol maintaining a pH of 5.0 in an ratio, 40:30:30 weigh 
accurately 5 mg of aceclofenac and 5 mg of tizanidine in 100 ml 
of meter flask and add 10ml of mobile phase and dissolve, and 
,make up the volume with mobile phase. From above stock 
solution, to prepare, 10µg/ml of aceclofenac and 20 µg/ml of 
tizanidine, it is prepared by diluting 2.4ml of stock solution in 
10ml of mobile phase. This liquid is better used for 
chromatogram recording [14]. 
Trial- 2 
The mobile phase that is used are Triethylamine: Acetonitrile 
maintaining a pH of 3.0 in an ratio, 50:50. Weigh accurately 5 
mg of aceclofenac and 5 mg of tizanidine in 100 ml of 
volumetric flask and add 10ml of mobile phase and dissolve and 
make up the capacity with mobile phase. From above stock 
solution, to prepare, 10µg/ml of aceclofenac and 20 µg/ml of 
tizanidine, it is prepared by diluting 2.4ml in 10ml of mobile 
phase. This liquid is better used for chromatogram recording 
[15]. 
 
Assay [16] 
Preparation of mixed standard solution 
Weigh accurately 5 mg of aceclofenac and 5 mg of tizanidine in 
100 ml of volumetric flask and dissolve in 10ml of mobile phase 
and make up the volume with mobile phase. From above stock 
solution 10µg/ml of aceclofenac and 20µg/ml of tizanidine is 
prepared by diluting 2.4ml in 10ml of mobile phase. This liquid 
is better used for chromatogram recording. 
Tablet sample 
10 tablets (each tablet contains aceclofenac -100 mg and 
tizanidine – 100 mg) were weighed and taken into a mortar and 
crushed to fine powder and uniformly mixed. Stock solutions of 
tizanidine and aceclofenac tablets (μg/ml) were made by 
solubilizing aceclofenac and tizanidine drugs equivalent to 5 mg 
in sufficient mobile phase. After that filter the solution using 
0.45-micron wheel filter and sonicate for five minutes and mix 
it up to 10 ml with mobile phase. Further dilutions are prepared 
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in 5 replicates of 20 μg/ml of tizanidine and 10µg/ml of 
aceclofenac was made by adding 2.4 ml of stock solution upto 
10 ml of mobile phase. 
Validation [17]. 
Linearity and range 
Standard stock solutions of aceclofenac and tizanidine (µg/ml) 
were prepared by dissolving 10 mg of aceclofenac and tizanidine 
in 10 ml of mobile phase and dilute and make up the volume to 
100 ml with mobile phase. 
Accuracy 
Accuracy of the method is determined by recovery studies. To 
the formulation (pre analyzed sample), the reference standards 
of the drugs were added at the level of 50%, 100%, 150%. The 
recovery studies were dole out three times and also the 
percentage recovery and percentage mean recovery were 
calculated. To check the accuracy of the maneuver, recovery 
studies were disbursed by addition of ordinary drug resolution to 
pre- analyzed sample solution at 3 totally different levels 50%, 
100%, 150%. 
Precision 
Method precisionPrepared sample preparations of tizanidine and 
aceclofenac as per test method and injected 6 times in to the 
column. The percentage recovery of tizanidine and aceclofenac 
should not be more than 2.0 %. 
Robustness 
To demonstrate the strength of the method, prepared solution as 
per test method and injected at completely different variable 
conditions like flow and wavelength. System suitableness 
parameters were compared there upon of technique preciseness. 
Ruggedness 
The strength of the tactic was studied by the determining the 
analyst to analyst variation by performing the Assay by 2 totally 
different analysts. The percentage relative standard deviation 
should be not more than 2.0 % 
 
RESULTS   
Determination of Wavelength of Aspirin and Clopidogrel 
using UV Visible Spectroscopy 
(X – Axis – Wavelength and Y – axis – Absorbance) 
The wavelength (λmax) at where maximum absorbance of the 
drug of 10 μg/ml concentration using methanol as solvent was 
scanned using UV-Visible spectrophotometer in the range of 
200–400 nm comparing methanol as blank. and the isobestic 
value was observed to be 230 nm for mixture of the medications. 
Method Development of Aceclofenac and Tizanidine  
Trial – 01 (X – Axis – Time and Y – axis – Voltage) 
 
Trial – 01 - The Efficiency was not satisfactory for aceclofenac and the baseline was not proper. Hence it was not taken for 
optimization. 
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Trial – 02 (X – Axis – Time and Y – axis – Voltage) 
 
Trial – 02 – In this trial, all the system suitability requirements were met. The peak asymmetry factor was below 2 for both tizanidine 
and aceclofenac. The efficiency was more than 2000 tizanidine and aceclofenac. Resolution between two peaks is >1.5. Hence, the 
method is taken for optimization 
Assay Results 
ACECLOFENAC TIZANIDINE 
 Standard Area Sample Area Standard Area Sample Area 
Injection-1 2334.362 2344.463 207.967 212.684 
Injection-2 2323.199 2351.614 199.968 209.655 
Injection-3 2337.863 2337.863 207.039 207.039 
Injection-4 2331.502 2334.732 207.632 210.092 
Injection-5 2328.483 2341.801 198.197 210.080 
Average Area 2331.082 2342.095 204.1606 209.91 
Standard deviation 6.489006 2.004044 
%RSD 0.276506 0.952806 
Assay(%purity) 100.27 102.61 
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The amount of Aceclofenac and Tizanidine present in the taken dosage form was found to be 100.27% and 102.61 % respectively. 
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Linearity of Aceclofenac and Tizanidine 
S. No. 
Aceclofenac Tizanidine 
Conc.(µg/ml ) Area Conc.(µg/ml ) Area 
1 5 1044.606 1 90.783 
2 7.5 1549.853 1.5 129.306 
3 10 2038.421 2 174.849 
4 12.5 2563.186 2.5 222.682 
5 15 3106.591 3 263.873 
 
 
 
The correlation coefficient for linear curve obtained between concentration vs. Area for standard preparations of aceclofenac and 
tizanidine is 0.99 and 0.98. The relationship between the concentration of aceclofenac and tizanidine and area of aceclofenac and 
tizanidine is linear in the range examined since all points lie in a straight line and hence the correlation coefficient is well within 
limits. 
 
Accuracy results for Aceclofenac and Tizanidine 
Recovery 
level 
Accuracy ACECLOFENAC Accuracy TIZANIDINE 
Amount 
taken 
(mcg/ml) 
Area 
% 
Recovery 
Average % 
Recovery 
Amount 
taken 
(mcg/ml) 
Area 
% 
Recovery 
Average % 
Recovery 
50% 
5 2326.313 
96.27 
100.28 
1 224.953 
103.20 
102.28 
5 2211.866 1 280.286 
5 2194.643 1 280.051 
100% 
10 2608.241 
101.86 
2 236.388 
97.60 10 2609.160 2 234.158 
10 2605.517 2 242.445 
150% 
15 3112.744 
102.72 
3 3112.744 
102.72 15 3109.681 3 267.053 
15 3106.682 3 269.916 
y = 205.49x + 5.6102
R² = 0.9996
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The percentage mean recovery should lie between 98 to 103 % and the percentage mean recovery of aceclofenac and tizanidine is 
100.28 % and 102.25 % respectively 
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Results for Method Precision of Aceclofenac and Tizanidine 
S. No. 
ACECLOFENAC TIZANIDINE 
Rt Area Rt Area 
1 2.510 2192.147 4.397 267.545 
2 2.523 2322.573 4.410 211.442 
3 2.523 2321.138 4.413 202.102 
4 2.523 2333.196 4.413 200.853 
5 2.507 2350.119 4.397 202.888 
6 2.497 2341.355 4.390 198.551 
Avg 2.513833 2310.088 4.403333 213.8968 
stdev 0.010926 58.82541 0.009893 21.512 
%RSD 0.433746 1.021 0.224216 0.0213 
 
 
 
 
The test results for Aceclofenac and tizanidine are showing that the %RSD within the acceptable limits. 
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Result of Robustness study 
Parameter ACECLOFENAC TIZANIDINE  
Retention time (min) Tailing factor Retention time (min) Tailing factor 
Flow Rate     
0.8 ml/min 3.130 1.258 5.443 1.167 
1.2 ml/min 2.090 1.036 3.663 0.943 
Wavelength     
233nm 2.513 1.222 4.380 1.088 
237nm 2.517 1.179 4.380 1.125 
 
 
From the observation it was found that the system suitability parameters were within the acceptable limits at all variable conditions. 
 
Results for Ruggedness 
ACECLOFENAC % Assay TIZANIDINE % Assay 
Analyst 01 99.36% Analyst 01 96.28% 
Anaylst 02 99.30% Anaylst 02 95.97% 
From the observation between the two analysts, it has been found out that, the percentage relative standard deviation should not 
greater than 2.0%, hence the method is considered as rugged. 
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The HPLC Technique is a very powerful separation tool in the 
determination of aceclofenac and tizanidine in pharmaceutical 
dosage forms. The analysis has been performed with various 
mobile phases which include, phosphate buffer: Acetonitrile: 
Methanol, and Triethylamine: Acetonitrile, which have provided 
optimization.  
 
Post optimization, validation parameters including, linearity and 
range, accuracy, precision, robustness, ruggedness, have been 
carried out according to ICH guidelines and indicated the 
procedure to be valid, specific, accurate and more easily 
reproducible within the limits, agreeable with the label claim. 
The low values of %RSD for method precision suggested that 
the method is precise. Linearity evaluated for the analyte peak 
showed a good linear response over a wide range of 
concentration 
CONCLUSION 
From the above experimental results and parameters it was 
concluded that, this newly developed method for the 
simultaneous estimation of Aceclofenac and Tizanidine was 
found to be simple, precise, accurate and the higher resolution 
and shorter retention time makes this method more acceptable 
and cost effective. As the advanced research is being continued 
followed up by developing drug combinations and multiple 
dosage forms, the method which has been performed,  it can be 
effectively applied for routine analysis in research institutions, 
quality control department in meant in industries, approved 
testing laboratories studies in near future. 
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